Anemia following zinc treatment for Wilson's disease: a case report and literature review

BMC Gastroenterol. 2019 Jul 9;19(1):120. doi: 10.1186/s12876-019-1038-5.

Abstract

Background: Zinc therapy is considered an effective and safe treatment for Wilson's disease. Hypocupremia-related anemia is rarely reported after long-term zinc administration or combination therapy with copper-chelating agent.

Case presentation: We herein report a 12-year-old girl with pre-symptomatic Wilson's disease diagnosed 5 years ago who presented with severe anemia after high-dose oral zinc for 4 years and 4 months. Her hemoglobin was gradually restored to the normal range after the adjustment of zinc dose and diet therapy for 4 months. A review of the literature revealed eight patients with hypocupremia-associated anemia following zinc therapy for Wilson's disease, including 7 adults and 1 child. The only child patient was a 16-year-old boy, in whom the zinc therapy was succession to penicillamine administration.

Conclusions: This is the first report worldwide that a child developed severe anemia following high-dose single zinc administration for Wilson's disease. It highlights the importance of regular follow-up during zinc treatment and the involvement of specialists in the long-term management of Wilson's disease. We hope that this will alert pediatricians the issue of zinc over-treatment.

Keywords: Anemia; Hepatolenticular degeneration; Hypocupremia; Wilson’s disease; Zinc.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anemia / chemically induced*
  • Child
  • Female
  • Hepatolenticular Degeneration / drug therapy*
  • Humans
  • Trace Elements / adverse effects*
  • Zinc / adverse effects*

Substances

  • Trace Elements
  • Zinc